Erratum: Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control (Oncogene (2009) 28 (651-661) DOI: 10.1038/onc.2008.419);Requirement for chromatin-remodeling complex in novel tumor suppressor HIC1-mediated transcriptional repression and growth control

Oncogene

Volumn 28, Issue 5, 2009, Pages 651-661

  Zhang, B ^a   Chambers, K J ^a   Leprince, D ^b   Faller, D V ^a   Wang, S ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b INSTITUT PASTEUR DE LILLE   (France)

Author keywords

Brg1; Cell cycle; E2F1; HIC1; SWI SNF; Transcription

Indexed keywords

BRG1 PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR SNF; TUMOR SUPPRESSOR PROTEIN; TUMOR SUPPRESSOR PROTEIN HIC1; UNCLASSIFIED DRUG;

ARTICLE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CELL CYCLE REGULATION; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; CONTROLLED STUDY; DNA BINDING; GENE FUNCTION; GENE INTERACTION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION REGULATION;

EID: 59649089064     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.388     Document Type: Erratum

References (38)

1. Aggerholm A, Holm MS, Guldberg P, Olesen LH, Hokland P. (2006). Promoter hypermethylation of p15, hic1, cdh1, and er is frequent in myelodysplastic syndrome and predicts poor prognosis in early-stage patients. Eur J Haematol 76: 23-32.
2. Banine F, Bartlett C, Gunawardena R, Muchardt C, Yaniv M, Knudsen ES et al. (2005). Swi/snf chromatin-remodeling factors induce changes in DNA methylation to promote transcriptional activation. Cancer Res 65: 3542-3547.
3. Bertrand S, Pinte S, Stankovic-Valentin N, Deltour-Balerdi S, Guerardel C, Begue A et al. (2004). Identification and developmental expression of the zebrafish orthologue of the tumor suppressor gene hic1. Biochim Biophys Acta 1678: 57-66.
4. Betz BL, Strobeck MW, Reisman DN, Knudsen ES, Weissman BE. (2002). Re-expression of hsnf5/ini1/baf47 in pediatric tumor cells leads to g1 arrest associated with induction of p16ink4a and activation of rb. Oncogene 21: 5193-5203.
5. Britschgi C, Rizzi M, Grob TJ, Tschan MP, Hugli B, Reddy VA et al. (2006). Identification of the p53 family-responsive element in the promoter region of the tumor suppressor gene hypermethylated in cancer 1. Oncogene 25: 2030-2039.
6. Chen W, Cooper TK, Zahnow CA, Overholtzer M, Zhao Z, Ladanyi M et al. (2004). Epigenetic and genetic loss of hic1 function accentuates the role of p53 in tumorigenesis. Cancer Cell 6: 387-398.
7. Chen WY, Baylin SB. (2005). Inactivation of tumor suppressor genes: choice between genetic and epigenetic routes. Cell Cycle 4: 10-12.
8. Chen WY, Wang DH, Yen RC, Luo J, Gu W, Baylin SB. (2005). Tumor suppressor hic1 directly regulates sirt1 to modulate p53-dependent DNA-damage responses. Cell 123: 437-448.
9. Chen WY, Zeng X, Carter MG, Morrell CN, Chiu Yen RW, Esteller M et al. (2003). Heterozygous disruption of hic1 predisposes mice to a gender-dependent spectrum of malignant tumors. Nat Genet 33: 197-202.
10. Chopin V, Leprince D. (2006). [Chromosome arm 17p13.3: Could hic1 be the one?]. Med Sci (Paris) 22: 54-61.
11. Dai Y, Ngo D, Forman LW, Qin DC, Jacob J, Faller DV. (2007). Sirtuin 1 is required for antagonist-induced transcriptional repression of androgen-responsive genes by the androgen receptor. Mol Endocrinol 21: 1807-1821.
12. Dai Y, Ngo D, Jacob J, Forman LW, Faller DV. (2008). Prohibitin and the swi/snf atpase subunit brg1 are required for effective androgen antagonist-mediated transcriptional repression of androgen receptor-regulated genes. Carcinogenesis 29: 1725-1733.
13. Dasgupta P, Sun J, Wang S, Fusaro G, Betts V, Padmanabhan J et al. (2004). Disruption of the rb-raf-1 interaction inhibits tumor growth and angiogenesis. Mol Cell Biol 24: 9527-9541.
14. Deltour S, Pinte S, Guerardel C, Wasylyk B, Leprince D. (2002). The human candidate tumor suppressor gene hic1 recruits ctbp through a degenerate gldlskk motif. Mol Cell Biol 22: 4890-4901.
15. Dunaief JL, Strober BE, Guha S, Khavari PA, Alin K, Luban J et al. (1994). The retinoblastoma protein and brg1 form a complex and cooperate to induce cell cycle arrest. Cell 79: 119-130.
16. Fusaro G, Wang S, Chellappan S. (2002). Differential regulation of rb family proteins and prohibitin during camptothecin-induced apoptosis. Oncogene 21: 4539-4548.
17. Giacinti C, Giordano A. (2006). Rb and cell cycle progression. Oncogene 25: 5220-5227.
18. Guerardel C, Deltour S, Leprince D. (1999). Evolutionary divergence in the broad complex, tramtrack and bric a brac/poxviruses and zinc finger domain from the candidate tumor suppressor gene hypermethylated in cancer. FEBS Lett 451: 253-256.
19. Inayoshi Y, Miyake K, Machida Y, Kaneoka H, Terajima M, Dohda T et al. (2006). Mammalian chromatin remodeling complex swi/snf is essential for enhanced expression of the albumin gene during liver development. J Biochem (Tokyo) 139: 177-188.
20. Lefebvre T, Pinte S, Guerardel C, Deltour S, Martin-Soudant N, Slomianny MC et al. (2004). The tumor suppressor hic1 (hypermethylated in cancer 1)is o-glcnac glycosylated. Eur J Biochem 271: 3843-3854.
21. Melki JR, Vincent PC, Clark SJ. (1999). Cancer-specific region of hypermethylation identified within the hic1 putative tumour suppressor gene in acute myeloid leukaemia. Leukemia 13: 877-883.
22. Nevins JR. (2001). The rb/e2f pathway and cancer. Hum Mol Genet 10: 699-703.
23. Nicoll G, Crichton DN, McDowell HE, Kernohan N, Hupp TR, Thompson AM. (2001). Expression of the hypermethylated in cancer gene (hic-1)is associated with good outcome in human breast cancer. Br J Cancer 85: 1878-1882.
24. Pinte S, Guerardel C, Deltour-Balerdi S, Godwin AK, Leprince D. (2004a) . Identification of a second g-c-rich promoter conserved in the human, murine and rat tumor suppressor genes hic1. Oncogene 23: 4023-4031.
25. Pinte S, Stankovic-Valentin N, Deltour S, Rood BR, Guerardel C, Leprince D. (2004b). The tumor suppressor gene hic1 (hypermethylated in cancer 1)is a sequence-specific transcriptional repressor: definition of its consensus binding sequence and analysis of its DNA binding and repressive properties. J Biol Chem 279: 38313-38324.
26. Stankovic-Valentin N, Verger A, Deltour-Balerdi S, Quinlan KG, Crossley M, Leprince D. (2006). A l225a substitution in the human tumour suppressor hic1 abolishes its interaction with the corepressor ctbp. FEBS J 273: 2879-2890.
27. Stevaux O, Dimova D, Frolov MV, Taylor-Harding B, Morris E, Dyson N. (2002). Distinct mechanisms of e2f regulation by drosophila rbf1 and rbf2. EMBO J 21: 4927-4937.
28. Strobeck MW, DeCristofaro MF, Banine F, Weissman BE, Sherman LS, Knudsen ES. (2001). The brg-1 subunit of the swi/snf complex regulates cd44 expression. J Biol Chem 276: 9273-9278.
29. Takahashi Y, Rayman JB, Dynlacht BD. (2000). Analysis of promoter binding by the e2f and prb families in vivo: distinct e2f proteins mediate activation and repression. Genes Dev 14: 804-816.
30. Waha A, Koch A, Hartmann W, Mack H, Schramm J, Sorensen N et al. (2004). Analysis of hic-1 methylation and transcription in human ependymomas. Int J Cancer 110: 542-549.
31. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. (2002a). Prohibitin co-localizes with rb in the nucleus and recruits n-cor and hdac1 for transcriptional repression. Oncogene 21: 8388-8396.
32. Wang S, Ghosh RN, Chellappan SP. (1998). Raf-1 physically interacts with rb and regulates its function: a link between mitogenic signaling and cell cycle regulation. Mol Cell Biol 18: 7487-7498.
33. Wang S, Nath N, Adlam M, Chellappan S. (1999a). Prohibitin, a potential tumor suppressor, interacts with rb and regulates e2f function. Oncogene 18: 3501-3510.
34. Wang S, Nath N, Minden A, Chellappan S. (1999b). Regulation of rb and e2f by signal transduction cascades: divergent effects of jnk1 and p38 kinases. EMBO J 18: 1559-1570.
35. Wong S, Weber JD. (2007). Deacetylation of the retinoblastoma tumour suppressor protein by sirt1. Biochem J 407: 451-460.
36. Wang S, Zhang B, Faller DV. (2002b). Prohibitin requires brg-1 and brm for the repression of e2f and cell growth. EMBO J 21: 3019-3028.
37. Wang S, Zhang B, Faller DV. (2004). Brg1/brm and prohibitin are required for growth suppression by estrogen antagonists. EMBO J 23: 2293-2303.
38. Zhang B, Chambers KJ, Faller DV, Wang S. (2007). Reprogramming of the swi/snf complex for co-activation or co-repression in prohibitin-mediated estrogen receptor regulation. Oncogene 26: 7153-7157.